According to the report, the global cytology and HPV testing market was valued at US$ 7.42 Bn in 2021 and is anticipated to expand at a CAGR of 5.9% from 2022 to 2030
According to the report, the global cytology and HPV testing market was valued at US$ 7.42 Bn in 2021 and is anticipated to expand at a CAGR of 5.9% from 2022 to 2030
Rising Incidence of Cervical Cancer Worldwide: Key Drivers
According to the American Cancer Society, cervical cancer is one of the most common causes of cancer death for in women in the U.S. In addition, according to the organization, it has been estimated that approximately 12,990 women in the U.S. would be diagnosed with cervical cancer and 4,120 deaths would occur from this disease in 2016.
Download Sample @ https://qyresearchmedical.com/sample/111633
However, as per various research studies conducted by the Centers for Disease Control and Prevention, the number of new cases of cervical cancer patients and the number of deaths due to cervical cancer have decreased significantly in the past 40 years i.e., between 1955 and 1992, the cervical cancer death rate declined by almost 70% in U.S.
The decline in death rate is attributed to factors such as increased use of Pap screening test and growing awareness among cervical cancer patients about screening tests available commercially in the market and the offered benefits for disease prevention
Thus, considering all the factors mentioned above, increasing prevalence rate of cervical cancer patients, growing awareness about disease prevention, and large-scale availability of screening kits and diagnostic products are expected to increase the adoption of diagnostic tests, thereby boosting the growth of the market
Thus, increasing incidence of cervical cancer is likely to boost the cytology and HPV testing market during the forecast period
High Incidence Rate of HPV Infection to Boost Market Growth
HPV infection is one of the most common causes of cervical cancer. It accounts for about 90% of cervical cancer cases and is diagnosed through Pap smear screening and HPV testing.
The spread of HPV infection poses a great threat to an individual’s immune system and leads to the conversion of normal cervix cells into cancerous cells. Two types of HPV infections — HPV 16 and HPV 18 — account for 70% of the overall cervical cancer cases and are termed as “high-risk” infections.
According to the World Health Organization (WHO), cervical cancer is the most prevalent HPV-related disease, with an estimated 530,000 new cases every year. Furthermore, according to the Cancer Research UK, about 3,100 women are diagnosed with cervical cancer each year in the country.
Various factors contributing to the high incidence rate of HPV infections include weakened immune system, smoking, chronic inflammation and long-term oral contraceptive use. The International Agency for Research and Cancer predicted that the rate of HPV related cervical cancer would rise by 40% in the near future.
Hence, HPV infection remains one of the leading causes of cervical cancer and rising prevalence and incidence rates are expected to drive the growth of the market
Lack of Appropriate Primary Healthcare Infrastructure to Hamper Market
Lack of proper healthcare infrastructure and the presence of outdated facilities in most of the developing countries and emerging markets are the biggest restraints of the cytology and HPV testing market
It has been observed that a large number of patients in many developing regions do not have access to modern primary healthcare infrastructure such as labs, clinics, diagnostic centers, equipment and supplies, and trained laboratory experts. Hence, inadequate and unreliable infrastructure deters the patient population from HPV and cytology testing.
Due to lack of primary care infrastructure for testing and diagnostics in various emerging countries such as Brazil, China and India, patients are constantly seeking treatment from hospitals, thereby raising the hospitalization cost rates. Consequently, most of the patients evade screening tests to avoid high hospitalization costs.
According to the Organization for Economic Co-operation and Development (OECD), Mexico spends 6.2% of its GDP on healthcare, which is lower than the average of 9.5% in OECD countries. This has resulted in lack of resources allocated for the country’s healthcare infrastructure leading to inappropriate medical care units such as operating rooms and insufficient beds.
Therefore, insufficiency and poor distribution of resources for constructing medical infrastructure is expected to impede the growth of the cytology and HPV testing market
Global Cytology and HPV Testing Market: Competitive Landscape
This report profiles major players in the global cytology and HPV testing market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
Leading players operating in the global cytology and HPV testing market are
- Becton
- Dickinson and Company
- Cepheid, Inc.
- Abbott Laboratories, Inc.
- F. Hoffmann-La Roche AG
- Fujirebio Diagnostics, Inc.
- Arbor Vita Corporation
- Hologic, Inc.
- QIAGEN N.V.
- OncoHealth Corporation
Global Cytology and HPV Testing Market: Key Developments
Key players in the global cytology and HPV Testing market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global cytology and HPV Testing market. A few expansion strategies adopted by players operating in the global cytology and HPV Testing market are:
In September 2015, Becton, Dickinson and Company (BD) launched the BD FACSCelesta, an advanced technique for BD cell analyzer portfolio, at the American Society for Cell Biology annual meeting. The coverage of cytometer facilitates high resolution cell population and measures 14 diverse single cell characteristics which is a perfect solution for researchers
In February 2015, the company acquired Signature Diagnostics, a genomics and translational oncology company. The acquisition would strengthen Roche’s next generation sequencing (NGS) diagnostics business. Roche will leverage Signature’s unique expertise in both biobanks and NGS assays to develop novel diagnostics for cancer patients.
In February 2014, Health Canada approved the use of Aptima HPV 16 18/45 Genotype Assay on Hologic’s Panther System. This completed the HPV portfolio on the popular and fully automated laboratory system.
The report on the global cytology and HPV Testing market discussed individual strategies, followed by company profiles of manufacturers of cytology and HPV Testing. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global cytology and HPV Testing market.
Key Questions Answered in Global Cytology and HPV Testing Market Report
- What is the scope of growth of companies in the global cytology and HPV testing market?
- What will be the Y-o-Y growth of the global cytology and HPV testing market between 2019 and 2027?
- What is the influence of changing trends in technologies on the global cytology and HPV testing market?
- Will North America continue to be the most profitable market for cytology and HPV testing providers?
- Which factors are anticipated to hamper the growth of the global cytology and HPV testing market during the forecast period?
- Which are the leading companies in the global cytology and HPV testing market?
Global Cytology and HPV Testing Market – Segmentation
Product Type
- HPV Testing
- Cytology Testing
Product Sub-types
- Assay Kits
- Systems
- Services
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111633/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/